See the DrugPatentWatch profile for lurbinectedin

Based on the information available, there is no specific guidance regarding the need for regular checks for long-term issues related to Lurbinectedin. Lurbinectedin is a novel anticancer drug that has been approved by the European Medicines Agency (EMA) for the treatment of relapsed small cell lung cancer (SCLC) [1].

However, as with any anticancer drug, Lurbinectedin can cause side effects, some of which may be long-term. These side effects can include myelosuppression, which is a decrease in the number of blood cells, including white blood cells, red blood cells, and platelets [1]. Patients receiving Lurbinectedin should have regular blood tests to monitor their blood cell counts [1].

Moreover, Lurbinectedin can also cause liver toxicity, which may lead to an increase in liver enzymes [1]. Therefore, patients receiving Lurbinectedin should have regular liver function tests to monitor for liver toxicity [1].

It is important to note that the long-term side effects of Lurbinectedin are still being studied, and the available data is limited [1]. Therefore, it is recommended that patients receiving Lurbinectedin should be closely monitored by their healthcare provider for any signs of long-term side effects [1].

In summary, while there is no specific guidance regarding the need for regular checks for long-term issues related to Lurbinectedin, patients receiving this drug should have regular blood tests and liver function tests to monitor for potential side effects.

Sources:
[1] DrugPatentWatch. "Lurbinectedin (PMID 33260023)" DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/lurbinectedin>.